LYRM2 and hepatocellular carcinoma: These data were further corroborated by the subcutaneous implantation and tail vein injection models, which revealed that HCC cells with LYRM2 knockdown exhibited reduced the subcutaneous tumour volumes and a lower rate and number of lung metastasis compared to those from the control group.